Get started
Bionano Genomics, Inc.Bionano Genomics, Inc.Bionano Genomics, Inc.

Bionano Genomics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

BNGO chart


Full chart

BNGO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪21.42 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.3104 USD
Net income (FY)
‪−232.49 M‬ USD
Revenue (FY)
‪36.12 M‬ USD
Shares float
‪101.47 M‬
Beta (1Y)
2.72

Employees


Employees (FY)
344
Change (1Y)
−61 −15.06%
Revenue / Employee (1Y)
‪104.99 K‬ USD
Net income / Employee (1Y)
‪−675.85 K‬ USD

About Bionano Genomics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Robert Erik Holmlin
Website
bionano.com
Headquarters
San Diego
Founded
2003
FIGI
BBG001KWWRS9
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BNGO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of BNGO is 0.2300 USD — it has increased by 4.38% in the past 24 hours. Watch Bionano Genomics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Bionano Genomics, Inc. stocks are traded under the ticker BNGO.
BNGO stock has risen by 6.93% compared to the previous week, the month change is a −9.01% fall, over the last year Bionano Genomics, Inc. has showed a −88.83% decrease.
We've gathered analysts' opinions on Bionano Genomics, Inc. future price: according to them, BNGO price has a max estimate of 1.00 USD and a min estimate of 1.00 USD. Watch BNGO chart and read a more detailed Bionano Genomics, Inc. stock forecast: see what analysts think of Bionano Genomics, Inc. and suggest that you do with its stocks.
BNGO reached its all-time high on Feb 16, 2021 with the price of 156.9000 USD, and its all-time low was 0.1940 USD and was reached on Dec 24, 2024. View more price dynamics on BNGO chart.
See other stocks reaching their highest and lowest prices.
BNGO stock is 31.40% volatile and has beta coefficient of 2.72. Track Bionano Genomics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Bionano Genomics, Inc. there?
Today Bionano Genomics, Inc. has the market capitalization of ‪21.42 M‬, it has decreased by −3.62% over the last week.
Yes, you can track Bionano Genomics, Inc. financials in yearly and quarterly reports right on TradingView.
Bionano Genomics, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
BNGO earnings for the last quarter are −0.52 USD per share, whereas the estimation was −0.20 USD resulting in a −163.26% surprise. The estimated earnings for the next quarter are −0.13 USD per share. See more details about Bionano Genomics, Inc. earnings.
Bionano Genomics, Inc. revenue for the last quarter amounts to ‪6.07 M‬ USD, despite the estimated figure of ‪7.76 M‬ USD. In the next quarter, revenue is expected to reach ‪6.30 M‬ USD.
BNGO net income for the last quarter is ‪−44.25 M‬ USD, while the quarter before that showed ‪−16.22 M‬ USD of net income which accounts for −172.72% change. Track more Bionano Genomics, Inc. financial stats to get the full picture.
No, BNGO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 344.00 employees. See our rating of the largest employees — is Bionano Genomics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Bionano Genomics, Inc. EBITDA is ‪−80.47 M‬ USD, and current EBITDA margin is −348.10%. See more stats in Bionano Genomics, Inc. financial statements.
Like other stocks, BNGO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bionano Genomics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Bionano Genomics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Bionano Genomics, Inc. stock shows the sell signal. See more of Bionano Genomics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.